Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Acucela slides after Otsuka ends ophthalmic deals

June 15, 2016 12:23 AM UTC

Acucela Inc. (Tokyo:4589) sank Y400 (24%) to Y1,253 on Tuesday after it said Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) terminated co-development deals for Acucela's emixustat (formerly ACU-4429) and Otsuka's OPA-6566.

Last month, Acucela said emixustat missed the primary endpoint of a Phase IIb/III study to treat geographic atrophy secondary to age-related macular degeneration (AMD) (see BioCentury Extra, May 26). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article